Bortezomib Pharma Grade API, designated model BORT-API-GMP-01, is a dipeptide boronic acid proteasome inhibitor with empirical formula C19H25BN4O4, CAS 179324-69-7, and molecular weight 384.24 g/mol. The material is released against a pharmacopoeial monograph-based specification suitable for tablet, capsule, granule, and lyophilized injection manufacture. It is supplied as a white to off-white powder. The molecule inhibits the 20S proteasome by reversible binding to the N-terminal threonine through its boronic acid terminal; this mechanism is distinct from irreversible epoxyketone proteasome inhibitors such as carfilzomib and from the orally bioavailable boronic acid derivative ixazomib. The API is intended for both injectable and oral investigational formulations, although the injectable route is the established pharmacopoeial dosage form.

In comparison with technical-grade bortezomib, the pharma-grade material is differentiated by full control of related substances, residual solvents, elemental impurities, chiral purity, polymorph identity, particle size, water content, and bacterial endotoxins. Unlike a finished lyophilized injection, it contains no mannitol or other cryoprotectant and is not sterile; final dosage form sterility is introduced later by aseptic filtration and lyophilization. The product therefore occupies an intermediate position between synthetic raw material and sterile finished drug product.

What Limits Residual Boronic Acid Reactivity in Wet Granulation and Direct Compression?

The boronic acid terminus can participate in reversible ester formation with polyol excipients, and aqueous processing may shift the equilibrium toward boronate esters or promote hydrolysis of the peptide backbone. Wet granulation is therefore not selected as a default route. For tablet and capsule development, direct compression or dry granulation is evaluated first. Low-dose blends require geometric dilution of the API with excipients, and final blend uniformity is measured according to Ph. Eur. 2.9.40 or USP <905>. Particle size is controlled by laser diffraction per ISO 13320; for direct compression, a D90 value below 100 µm is often required to achieve acceptable content uniformity when unit doses are in the milligram range. If the API is roller-compacted for granule production, ribbon density and mill screen size are qualified to avoid overcompaction and to preserve granule flow.

Solid-state characterization is performed by X-ray powder diffraction and differential scanning calorimetry. If amorphous content is present or generated during grinding, storage stability and dissolution can shift because amorphous regions recrystallize with changes in temperature and relative humidity. Tableting operations are performed on a rotary tablet press with contained handling because bortezomib is classed as a hazardous drug in many institutional hygiene plans; this containment requirement also affects isolator design and cleaning-validation protocols. Blend flow is assessed by bulk and tapped density determinations, and content uniformity acceptance is established with AV ≤ 15 under USP <905> unless the final dosage form is justified under reduced sample-size criteria.

Granule manufacture for sachet or capsule filling uses dry granulation or roller compaction when the API is moisture-sensitive. Granule size distribution is controlled by sieve analysis or laser diffraction, and residual moisture is limited by Karl Fischer titration. Direct compression blends containing low-dose bortezomib are sensitive to segregation in transfer lines and hopper discharge; sampling points during compression are selected to detect segregation across extended run times.

Injectable-Grade Controls Across Endotoxin, Particulate Matter, and Lyophilization Interface

For injectable manufacture, the API is not required to be sterile; instead, it is supplied as a low-bioburden material with controlled endotoxin. The final injectable solution is typically prepared by dissolving the API in a buffered or water-containing vehicle, followed by sterilizing-grade filtration through a 0.22 µm membrane and aseptic lyophilization. Terminal heat sterilization is generally avoided because bortezomib is heat-sensitive in aqueous solution. The lyophilization process commonly includes mannitol as a cryoprotectant and ester-forming excipient; the reversible mannitol-boronate equilibrium is pH-dependent and influences reconstitution time and cake appearance.

Lyophilizer thermal mapping and shelf-temperature uniformity should be qualified to ±1.0 °C, and the cycle should include a freezing temperature at or below −40 °C, followed by primary and secondary drying stages under vacuum. Endotoxin limits are calculated from the maximum intended parenteral dose using USP <85> or Ph. Eur. 2.6.14; for intravenous administration, the endotoxin limit derives from a K value of 5 EU/kg. Particulate matter in the finished injection is controlled under USP <788>. Sterile filtration compatibility, filter extractables, and solution hold-time studies are performed on the compounded solution because bortezomib can degrade if held too long before lyophilization; the product label defines the in-use hold time after reconstitution.

When Oral Dosage Forms Are Prepared from a Parenteral-Optimized API Grade

Transferring the same API lot to oral solid dosage forms changes the criticality of certain attributes. Particle size and bulk density become more important for solid dose processing than for injectable manufacture, while endotoxin and particulate matter are less critical. The API may need to be coarsened or excipient-blended to reduce segregation in low-dose tablet and capsule formulations. Dry granulation may be preferred over direct compression if API bulk density is low; roller compaction parameters such as roll pressure, roll speed, and gap are defined during development and linked to granule particle size and compressibility.

Tablets and capsules produced from the API are generally non-sterile and are subject to microbial limits rather than sterility. Granules may be filled into capsules or sachets; all solid-oral processes require careful control of water activity and residual moisture because the boronic acid group can be hydrolytically labile. Published data for oral bortezomib tablet, capsule, or granule configurations is limited, and no major pharmacopoeial monograph defines an oral bortezomib finished product. Consequently, oral formulation development requires separate preformulation stability and bioavailability studies.

Compared with a bortezomib finished injection, the API does not include mannitol, does not have an assigned pH after reconstitution, and is not sterile. Compared with oral ixazomib, bortezomib has a different peptide backbone and is not considered bioequivalent; it cannot be substituted directly in oral formulation platforms without new bioavailability data. Compared with technical-grade bortezomib, the pharma-grade API carries a full release dossier that supports injectable-grade endotoxin control and solid-dose particle size control in the same supply chain.

Residual Solvent and Elemental Impurity Verification Against ICH Q3C and Q3D

Residual solvents are controlled because bortezomib synthetic routes may involve polar aprotic and chlorinated solvents. Limits are aligned with ICH Q3C(R8) and verified by headspace gas chromatography. If a synthetic route does not use a particular solvent, its limit is not required in the specification. Elemental impurities are controlled according to ICH Q3D(R2); Class 1 limits for arsenic, cadmium, lead, and mercury are applied unless route-specific risk assessment justifies alternative controls. The API release specification also includes chiral purity by chiral HPLC, related substances by high-performance liquid chromatography, and water content by Karl Fischer titration. Manufacturing is conducted under ICH Q7 for active pharmaceutical ingredients; finished sterile dosage manufacturing follows EU GMP Annex 1 and applicable national GMP regulations.

The following default Class 2 solvent limits apply when the corresponding solvent is present in the manufacturing process. Limits are taken from ICH Q3C(R8) and are expressed as concentration limits because Class 2 solvents have permitted daily exposure values.

Batch-to-batch consistency is evaluated by comparing the certificate of analysis against the approved specification and by trending impurity profiles. For solid oral manufacture, bulk density and particle size are also trended because shifts in these properties can alter tablet weight and blend uniformity. For injectable manufacture, bioburden and endotoxin trends are used to define release limits and to support the maximum hold time before aseptic filtration. The pharma-grade material therefore differs from unqualified bulk powder through its defined specification, impurity controls, and compatibility with both oral solid-dose and parenteral unit operations.